Apremilast 30 mg twice daily combined with dupilumab for the treatment of recalcitrant moderate-to-severe atopic dermatitis

J Eur Acad Dermatol Venereol. 2023 Jun;37(6):e765-e767. doi: 10.1111/jdv.18906. Epub 2023 Feb 8.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antibodies, Monoclonal, Humanized / therapeutic use
  • Dermatitis, Atopic* / drug therapy
  • Double-Blind Method
  • Humans
  • Severity of Illness Index
  • Thalidomide / therapeutic use
  • Treatment Outcome

Substances

  • dupilumab
  • apremilast
  • Antibodies, Monoclonal, Humanized
  • Thalidomide

Grants and funding